WO2006117666A3 - Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery - Google Patents

Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery Download PDF

Info

Publication number
WO2006117666A3
WO2006117666A3 PCT/IB2006/001158 IB2006001158W WO2006117666A3 WO 2006117666 A3 WO2006117666 A3 WO 2006117666A3 IB 2006001158 W IB2006001158 W IB 2006001158W WO 2006117666 A3 WO2006117666 A3 WO 2006117666A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
sub
pharmaceutical compositions
methods
tenon
Prior art date
Application number
PCT/IB2006/001158
Other languages
French (fr)
Other versions
WO2006117666A2 (en
Inventor
Channing Rodney Beals
Wesley Warren Day
Deborah Anne Khalil
Karen Jean Klamerus
Susan Renee Raber
Baldo Scassellati-Sorzolini
Samuel Hyman Zwillich
Original Assignee
Pfizer
Channing Rodney Beals
Wesley Warren Day
Deborah Anne Khalil
Karen Jean Klamerus
Susan Renee Raber
Baldo Scassellati-Sorzolini
Samuel Hyman Zwillich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Channing Rodney Beals, Wesley Warren Day, Deborah Anne Khalil, Karen Jean Klamerus, Susan Renee Raber, Baldo Scassellati-Sorzolini, Samuel Hyman Zwillich filed Critical Pfizer
Publication of WO2006117666A2 publication Critical patent/WO2006117666A2/en
Publication of WO2006117666A3 publication Critical patent/WO2006117666A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

The invention provides dosage forms of compounds of Formula (I), (II) or (III), or pharmaceutically acceptable salts or solvates thereof, and pharmaceutical compositions thereof, for sub-Tenon administration to the posterior segment of the eye proximate the macula in a mammal with age-related macular degeneration. The invention further provides methods of treating age-related macular degeneration in a mammal by administering these dosage forms.
PCT/IB2006/001158 2005-04-29 2006-04-18 Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery WO2006117666A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67606005P 2005-04-29 2005-04-29
US60/676,060 2005-04-29

Publications (2)

Publication Number Publication Date
WO2006117666A2 WO2006117666A2 (en) 2006-11-09
WO2006117666A3 true WO2006117666A3 (en) 2007-01-18

Family

ID=37055940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001158 WO2006117666A2 (en) 2005-04-29 2006-04-18 Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery

Country Status (4)

Country Link
JP (1) JP2006306877A (en)
AR (1) AR054442A1 (en)
TW (1) TW200719893A (en)
WO (1) WO2006117666A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008006379A (en) * 2005-11-29 2009-03-03 Smithkline Beecham Corp Treatment method.
JO3387B1 (en) 2011-12-16 2019-03-13 Glaxosmithkline Llc Derivatives of betulin
CA2893959A1 (en) * 2012-12-14 2014-06-19 Shenshen Cai Pharmaceutical compositions
BR112017006005A2 (en) 2014-09-26 2017-12-19 Glaxosmithkline Ip No 2 Ltd pharmaceutical composition, and method of preventing or treating a hiv infection.
JP2018065920A (en) * 2016-10-19 2018-04-26 中越パルプ工業株式会社 Cellulose nanofiber and method for producing cellulose nanofiber
CN116251186A (en) * 2021-12-09 2023-06-13 成都瑞沐生物医药科技有限公司 Tyrosine kinase inhibitor ophthalmic preparation and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531491B1 (en) * 1999-07-02 2003-03-11 Agouron Pharamaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2003106462A1 (en) * 2002-06-14 2003-12-24 Pfizer Inc. Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
WO2004056806A1 (en) * 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531491B1 (en) * 1999-07-02 2003-03-11 Agouron Pharamaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2003106462A1 (en) * 2002-06-14 2003-12-24 Pfizer Inc. Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
WO2004056806A1 (en) * 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GALE D C ET AL: "Ocular pharmacokinetics in single compound and cassette dose studies following sub-Tenon administration in Dutch-belted rabbits", IOVS, vol. 46, no. Suppl. S, 2005, & ANNUAL MEETING OF THE ASSOCIATION-FOR-RESEARCH-IN-VISION-AND-OPHTHALM OLOGY; FT LAUDERDALE, FL, USA; MAY 01 -05, 2005, pages 5381, XP009073501, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
JP2006306877A (en) 2006-11-09
WO2006117666A2 (en) 2006-11-09
TW200719893A (en) 2007-06-01
AR054442A1 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
WO2007046083A3 (en) Compositions for treatment of eye diseases
MX344036B (en) Compositions comprising azelastine and methods of use thereof.
MX337100B (en) Alkoxy compounds for disease treatment.
PH12015501208A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
WO2009035673A8 (en) Compositions and methods for treating macular degeneration
BR112015029512A2 (en) pyrazolopyrrolidine derivatives and their use in the treatment of diseases
EA200870423A1 (en) DERIVATIVES OF TRIAZOLPYRAZINES APPLICABLE AS ANTI-CANCER AGENTS
BRPI0811142A8 (en) prevention and treatment of eye conditions associated with supplements
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
EA201000091A1 (en) DERIVATIVES OF MORFOLINOPYRIMIDINE USED IN DISEASES ASSOCIATED WITH mTOR KINASE AND / OR PI3K
UA102517C2 (en) Substituted morpholine and thiomorpholine derivatives, pharmaceutical composition based thereon and use thereof for the preparation of medicament for the treatment of a disorder or disease of the central nervous system
WO2006117666A3 (en) Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
MX2008002061A (en) Thiazolyl piperidine derivatives.
MX2010000351A (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders.
TW200626158A (en) Naphthaline derivatives
BR112015029401A8 (en) pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination
MXPA05007857A (en) Indole-derivative modulators of steroid hormone nuclear receptors.
EA200900582A1 (en) PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF EYE PATHOLOGIES
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
MX2007006387A (en) 3-substituted pyridine derivatives as h3 antagonists.
WO2008020032A8 (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
WO2006077024A3 (en) 5-aminoindole derivatives
MX2007007027A (en) Piperazinyl pyridine derivatives as anti-obesity agents.
WO2010005580A3 (en) Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06755857

Country of ref document: EP

Kind code of ref document: A2